Positive News SentimentPositive NewsNASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $37.16 +0.01 (+0.01%) As of 09:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AtriCure Stock (NASDAQ:ATRC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AtriCure alerts:Sign Up Key Stats Today's Range$37.46▼$37.4650-Day Range$34.12▼$37.8752-Week Range$27.64▼$43.11Volume1,625 shsAverage Volume545,303 shsMarket Capitalization$1.85 billionP/E RatioN/ADividend YieldN/APrice Target$50.89Consensus RatingModerate Buy Company Overview AtriCure, Inc. is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF. The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques. In addition, AtriCure markets the LARIAT Suture Delivery Device for left atrial appendage closure to help reduce stroke risk in AF patients who are unable to tolerate long-term anticoagulation therapy. AtriCure continues to invest in R&D initiatives aimed at expanding its surgical and hybrid EP solutions, as well as digital platforms for intraoperative mapping and post-procedural monitoring. AtriCure operates internationally with sales and distribution channels across North America, Europe, Asia and select emerging markets. The company collaborates with leading cardiac centers, physician innovators and academic institutions to conduct clinical studies and training programs that support adoption of its technologies. Under the leadership of President and Chief Executive Officer Jonathan M. Cathcart, AtriCure has pursued strategic partnerships and targeted acquisitions to enhance its electrophysiology portfolio and drive long-term growth. The company remains committed to expanding access to safe, effective AF treatments and advancing the standard of care in cardiac surgery and electrophysiology.AI Generated. May Contain Errors. Read More AtriCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreATRC MarketRank™: AtriCure scored higher than 61% of companies evaluated by MarketBeat, and ranked 379th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingAtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 9 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAtriCure has a consensus price target of $50.89, representing about 35.8% upside from its current price of $37.46.Amount of Analyst CoverageAtriCure has only been the subject of 2 research reports in the past 90 days.Read more about AtriCure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.60) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -48.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -48.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.45% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in AtriCure has recently increased by 7.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.45% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in AtriCure has recently increased by 7.28%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentAtriCure has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for AtriCure this week, compared to 6 articles on an average week.Search Interest4 people have searched for ATRC on MarketBeat in the last 30 days. MarketBeat Follows2 people have added AtriCure to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $655,633.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRC Stock News HeadlinesAtriCure, Inc. (NASDAQ:ATRC) Given Average Rating of "Moderate Buy" by BrokeragesOctober 11, 2025 | americanbankingnews.comAtriCure Sees RS Rating Improve To 73October 10, 2025 | msn.comThis dark force is about to change everythingAn unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.October 21 at 2:00 AM | Porter & Company (Ad)AtriCure to Announce Third Quarter 2025 Financial ResultsOctober 8, 2025 | businesswire.comStocks With Rising Relative Strength: AtriCureSeptember 19, 2025 | msn.comIBD Rating Upgrades: AtriCure Flashes Improved Price StrengthSeptember 17, 2025 | msn.comAtriCure (ATRC) Unveils cryoXT Device for Advanced Post-Amputation Pain ManagementSeptember 10, 2025 | finance.yahoo.comAtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following AmputationSeptember 9, 2025 | finance.yahoo.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $30.56 at the beginning of the year. Since then, ATRC stock has increased by 22.6% and is now trading at $37.46. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings data on Tuesday, July, 29th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.13. The firm's quarterly revenue was up 17.1% on a year-over-year basis. Read the conference call transcript. Does AtriCure have any subsidiaries? AtriCure subsidiaries include these companies: SentreHEART. Who are AtriCure's major shareholders? AtriCure's top institutional shareholders include Voya Investment Management LLC (1.42%), Diversified Trust Co (0.07%), Harbor Capital Advisors Inc. (0.06%) and Blue Trust Inc. (0.02%). Insiders that own company stock include Salvatore Privitera, Justin J Noznesky, Vinayak Doraiswamy, Karl S Dahlquist, Sven Wehrwein, Regina E Groves, Karen Prange and Maggie Yuen. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD). Company Calendar Last Earnings7/29/2025Today10/20/2025Next Earnings (Confirmed)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,300Year Founded2000Price Target and Rating Average Price Target for AtriCure$50.89 High Price Target$60.00 Low Price Target$45.00 Potential Upside/Downside+35.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.70 million Net Margins-7.27% Pretax Margin-7.05% Return on Equity-4.20% Return on Assets-3.19% Debt Debt-to-Equity Ratio0.16 Current Ratio3.94 Quick Ratio2.83 Sales & Book Value Annual Sales$465.31 million Price / Sales4.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book3.96Miscellaneous Outstanding Shares49,700,000Free Float47,961,000Market Cap$1.86 billion OptionableOptionable Beta1.59 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ATRC) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.